374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

373: Party in biotech land and AstraZeneca’s miscalculation

372: A pharma C-suite shakeup and Trump's deal with Pfizer

371: A gene therapy success in Huntington's and Trump's autism announcement

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

369: Trump, Chinese biotech, and an industry career reshaped by illness

368: New stakes in the vaccine dispute and a boost for biotech

367: The ouster of CDC's director, biotech venture firm rankings

366: Viking’s obesity flop, ‘pharma to table’ drug sales

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

363: What Vinay Prasad’s ouster means for biotech and the FDA

362: A mother’s perspective on Sarepta’s gene therapy halt

361: Inside an FDA drug rejection, and layoffs at Sarepta

360: NIH grant cuts, FDA transparency questions and biotech M&A

359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

358: FDA's gene therapy turmoil, and an alternative model for funding research

357: The upheaval of CDC's vaccine panel, and drug pricing confusion

356: An AI experiment at the FDA & Novo trailing in the obesity drug race

355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview